Fabry Disease

Overview

Fabry disease is a rare, inherited X-linked disorder caused by disease-causing variants in the GLA gene. These variants reduce or eliminate alpha-galactosidase A (α-Gal A), an enzyme that normally breaks down certain fatty substances. Without enough α-Gal A, globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) accumulate in cells, progressively damaging the kidneys, heart, nerves, blood vessels, skin, eyes, and gastrointestinal system. Classical Fabry disease often begins in childhood or adolescence, particularly in males, with severe burning pain, reduced sweating, skin lesions, and later kidney, cardiac, and stroke-related complications; females can also have substantial disease, although severity is highly variable. GeneReviews: Fabry Disease

Without effective disease-specific treatment, Fabry disease can lead to kidney failure, cardiomyopathy, arrhythmias, stroke, and premature death. Current standard care is enzyme replacement therapy (ERT), usually intravenous recombinant α-Gal A given repeatedly for life, or the oral pharmacological chaperone migalastat for people with specific “amenable” GLA variants; treatment also includes kidney, cardiac, neurologic, and pain management. These treatments can slow or prevent some progression, especially when started early, but do not repair the inherited gene defect and may not fully reverse established organ injury. GeneReviews: Fabry Disease

Scope of Recent Research (2020–present)

Research since 2020 has been active and increasingly focused on achieving durable endogenous production of α-Gal A rather than repeatedly infusing manufactured enzyme. The leading curative-intent strategy is one-time gene addition, especially liver-directed adeno-associated virus (AAV) therapy; parallel work includes heart-targeted AAV vectors, edited liver “protein factories,” blood stem-cell gene therapy, messenger RNA (mRNA), and non-viral nanoparticle delivery. The field is closer to a potentially durable treatment than at any earlier point, but no therapy has yet demonstrated a permanent cure across all Fabry manifestations or received approval as a curative treatment. Progress and Challenges in the Treatment of Fabry Disease

Major Breakthroughs and Emerging Therapies

The clearest clinical advance is isaralgagene civaparvovec (ST-920), a liver-directed AAV2/6 gene-addition therapy from Sangamo Therapeutics. A single intravenous infusion delivers a functioning human GLA complementary DNA sequence to liver cells, which are intended to release α-Gal A continuously into the bloodstream for uptake by other tissues. In the Phase 1/2 STAAR study, Sangamo reported sustained α-Gal A activity in the longest-followed participant for up to 4.5 years, with all 18 participants who entered on ERT reported to have remained off ERT at the June 2025 analysis. These are promising company-reported findings, but they are not equivalent to proof that every affected organ has been permanently corrected. STAAR topline results

In 2026, ST-920 became the most advanced Fabry gene-therapy regulatory effort. Sangamo reported that it had initiated a rolling U.S. biologics license application (BLA) in December 2025 and had submitted its preclinical and clinical modules to the Food and Drug Administration by March 9, 2026. The company stated that the FDA had agreed that the 52-week estimated glomerular filtration rate (eGFR) slope could support an accelerated-approval pathway; this is an important milestone, but regulatory submission and review are not approval, and confirmatory evidence of long-term clinical benefit remains necessary. Sangamo BLA update

A second gene-addition approach, 4D-310 from 4D Molecular Therapeutics, uses an AAV vector designed to target the heart more efficiently, aiming to address Fabry cardiomyopathy directly. Early reports in six treated adults described increased α-Gal A activity and signals of improved cardiac function, exercise capacity, and quality of life after one infusion. However, the program also exposed a major safety challenge: three of six treated participants developed atypical hemolytic uremic syndrome, a serious disorder involving blood-cell destruction, low platelets, and kidney injury. The trials moved into follow-up rather than additional enrollment, illustrating both the potential and the risk of high-dose systemic AAV treatment. Progress and Challenges in the Treatment of Fabry Disease 4D-310 trial record

Gene editing remains preclinical but could theoretically offer a more permanent solution. A 2021 Fabry-mouse study used zinc-finger nucleases to insert a human GLA sequence into the albumin locus in liver cells, turning the liver into a continuing source of α-Gal A. The edited mice achieved very high circulating enzyme activity and reduced disease substrate in key tissues. Unlike conventional AAV gene addition, this approach seeks a targeted genomic insertion, but it must still establish safe, efficient editing, durable benefit, and acceptable immune effects in humans. ZFN-mediated in vivo gene editing in Fabry mice

Other experimental work aims to avoid viral vectors or enable repeat dosing. Researchers have shown that solid-lipid nanoparticles carrying GLA plasmid DNA can raise α-Gal A activity in Fabry mice, including in heart and kidney, and galactomannan-coated versions were designed to preferentially direct delivery toward the liver. Separately, α-Gal A mRNA packaged in lipid nanoparticles is being studied as a temporary, repeatable way to make the body produce enzyme; recent metabolic work in Fabry-model mice supports its biological activity, but this remains preclinical rather than a cure. Non-viral gene therapy in Fabry mice Galactomannan-decorated lipid nanocarrier α-Gal A mRNA metabolic study

Clinical Trials and Experimental Approaches

The registrational Phase 1/2 STAAR trial of ST-920 enrolled adults with Fabry disease who were ERT-naive, off ERT, or receiving ERT. In Sangamo’s June 2025 report, 32 dosed participants had a mean annualized eGFR slope of +1.965 mL/min/1.73 m²/year at 52 weeks, while the 19 participants with 104-week follow-up had a mean slope of +1.747 mL/min/1.73 m²/year. The company also reported stable lyso-Gb3 after ERT withdrawal, improvements in patient-reported quality-of-life measures, and mostly mild or moderate adverse events. Because STAAR is open-label, dose-ranging, and lacks a randomized control group, these findings require cautious interpretation against the variable natural course of Fabry disease. STAAR topline results STAAR trial record

The 4D-310 Phase 1/2 studies remain notable for their attempt to target cardiac disease, but safety has limited development: as of January 2023, 4D Molecular Therapeutics said that no additional participants would be enrolled in the then-current Fabry studies. 4DMT pipeline update Earlier, autologous CD34-positive blood stem-cell gene therapy AVR-RD-01 reported that five adult men received their own lentivirus-modified stem cells and that three chose to stop ERT; however, Avrobio deprioritized the program in 2022, citing variable responses alongside market and regulatory challenges. Lentivirus-mediated gene therapy for Fabry disease Avrobio 2023 annual report

Freeline’s liver-directed AAV program, FLT190, also provided preclinical proof that liver-produced α-Gal A could lower Gb3 and lyso-Gb3 in animal models, but the company paused further Fabry development in 2023 to concentrate resources on another program. This attrition matters: it shows that promising gene-therapy biology alone does not guarantee a sustainable clinical-development path. FLT190 preclinical evaluation Freeline program update

Methodologies and Scientific Approaches

Fabry cure research commonly uses Gla-deficient mouse models, patient-derived cells, and non-human primates to test whether a treatment restores α-Gal A activity and reduces Gb3 and lyso-Gb3. Liver-directed strategies rely on the principle of cross-correction: liver cells manufacture and secrete α-Gal A, then other cells take it up through enzyme-trafficking pathways. Heart-directed vectors instead seek direct enzyme production in cardiomyocytes, while ex vivo stem-cell approaches modify a patient’s own blood-forming cells before reinfusion. ZFN-mediated in vivo gene editing in Fabry mice FLT190 preclinical evaluation

Researchers monitor enzyme activity, plasma and urine lyso-Gb3/Gb3, kidney filtration measured by eGFR, protein in urine, cardiac imaging, exercise testing, pain, and quality of life. However, no single biomarker is universally accepted as a surrogate for long-term organ preservation, so studies increasingly combine biochemical measures with kidney biopsy findings, cardiac measures, and patient-reported outcomes. GeneReviews: Fabry Disease Urine biomarker study The role of kidney biopsy in Fabry disease

Leading Institutions and Funding

Sangamo Therapeutics leads the most advanced liver-directed AAV program, ST-920, with its global STAAR trial and BLA effort. 4D Molecular Therapeutics has led the heart-targeted AAV approach with 4D-310, while investigators associated with the earlier lentiviral program established clinical proof of concept for autologous blood stem-cell gene therapy. Academic groups at the University of the Basque Country’s PharmaNanoGene program have been prominent in non-viral lipid-nanoparticle GLA delivery research. Sangamo BLA update Lentivirus-mediated gene therapy for Fabry disease Galactomannan-decorated lipid nanocarrier

Funding is a practical determinant of progress in this small-population disease. Commercial sponsors fund most late-stage Fabry gene-therapy development, while patient organizations such as the National Fabry Disease Foundation report providing occasional support for smaller research projects and education initiatives. The discontinuation or pausing of AVR-RD-01 and FLT190 also demonstrates how financing, regulatory uncertainty, and competing pipeline priorities can interrupt research even after encouraging early data. National Fabry Disease Foundation community landscape Avrobio 2023 annual report Freeline program update

Strengths, Limitations, and Challenges

The central strength of current gene-addition strategies is that even a modest, durable supply of α-Gal A could reduce or eliminate the lifelong infusion burden of ERT and provide broader exposure to enzyme than intermittent replacement. ST-920 has generated the strongest clinical durability signal so far, including multi-year enzyme expression and sustained ERT withdrawal in treated participants. Gene editing and non-viral delivery may eventually permit more controlled or repeatable dosing than conventional AAV therapy. STAAR topline results ZFN-mediated in vivo gene editing in Fabry mice Non-viral gene therapy in Fabry mice

The limitations are substantial. AAV therapies can provoke immune reactions, may be unsuitable for people with pre-existing antibodies to the vector, and are difficult to redose. They also may not reverse fibrosis, scarring, or irreversible damage already present in the heart, kidneys, or nervous system. The atypical hemolytic uremic syndrome cases in the 4D-310 program underline the importance of dose, tissue targeting, complement activation, immune suppression, and long-term safety surveillance. Finally, small, heterogeneous, open-label trials and uncertain surrogate biomarkers make it difficult to distinguish true long-term disease modification from short-term biochemical improvement. Progress and Challenges in the Treatment of Fabry Disease 4D-310 trial record

Outlook and Future Directions

As of August 8, 2026, Fabry disease does not have a proven cure, but ST-920 has moved the field into a pivotal regulatory phase and is the leading candidate for a one-time disease-modifying treatment. The most important milestones will be completion and outcome of FDA review; independent publication of the full STAAR dataset; longer follow-up showing durable kidney, heart, neurologic, and survival benefit; and evidence that gene therapy can be delivered safely to people with advanced disease, women with variable disease expression, and patients with pre-existing AAV immunity. If those hurdles are cleared, gene addition may become the first practical route toward a functional cure; true gene correction and repeat-dose non-viral platforms are likely to require longer preclinical and clinical development. Sangamo BLA update Progress and Challenges in the Treatment of Fabry Disease

References

• GeneReviews: Fabry Disease — Mehta and Hughes, University of Washington, 2024.
• Progress and Challenges in the Treatment of Fabry Disease — Argirò et al., 2025.
• STAAR topline results — Sangamo Therapeutics, 2025.
• Sangamo BLA update — Sangamo Therapeutics, 2026.
• 4D-310 trial record — ClinicalTrials.gov, 2026.
• ZFN-mediated in vivo gene editing in Fabry mice — Sharma et al., 2021.
• Non-viral gene therapy in Fabry mice — Rodríguez-Castejón et al., 2021.
• Galactomannan-decorated lipid nanocarrier — Rodríguez-Castejón et al., 2022.
• α-Gal A mRNA metabolic study — Chung et al., 2024.
• STAAR trial record — ClinicalTrials.gov, 2026.
• 4DMT pipeline update — 4D Molecular Therapeutics, 2023.
• Lentivirus-mediated gene therapy for Fabry disease — Khan et al., 2021.
• Avrobio 2023 annual report — Avrobio, 2023.
• FLT190 preclinical evaluation — Mead et al., 2023.
• Freeline program update — Fabry International Network, 2023.
• Urine biomarker study — ClinicalTrials.gov, 2025.
• The role of kidney biopsy in Fabry disease — Mignani et al., 2025.
• National Fabry Disease Foundation community landscape — National Fabry Disease Foundation, 2020.